Vivo Capital
Palo Alto, CAfiles as Vivo Capital, LLC
$1.1bn in 47 US stocks at the end of 30 June 2026. The top 10 are 52.4% of the money. It changed about 27.1% of the portfolio this quarter.
Value
$1.1bn
Stocks
47
Top 10 share
52.4%
Turnover
27.1%
What changed this quarter
New
Bought for the first time this quarter.
- Achieve Life SciencesACHV1.6% of the fund
- Editas MedicineEDIT1.1% of the fund
- Odyssey TherapeuticsODTX1.0% of the fund
- Aura BiosciencesAURA0.8% of the fund
- Avalo TherapeuticsAVTX0.5% of the fund
- Valneva SEVALN0.4% of the fund
- InMed PharmaceuticalsINM0.1% of the fund
Added
Bought more of a stock they already held.
- ArriVent BioPharmaAVBP5.3% of the fund+90%
- Abivax SAABVX5.0% of the fund+73%
- Tenax TherapeuticsTENX3.3% of the fund+1100%
- Alto NeuroscienceANRO2.9% of the fund+17%
- MoonLake ImmunotherapeuticsMLTX2.5% of the fund+40%
Cut
Sold some of their stake.
- Praxis Precision MedicinesPRAX8.3% of the fund-20%
- ErascaERAS6.9% of the fund-66%
- Tango TherapeuticsTNGX3.9% of the fund-36%
- DBV Technologies S ADBVT2.8% of the fund-31%
- SAB BiotherapeuticsSABS2.6% of the fund-36%
- Compass TherapeuticsCMPX1.6% of the fund-19%
- Unicycive TherapeuticsUNCY0.2% of the fund-69%
- Pasithea TherapeuticsKTTA<0.1% of the fund-78%
Sold out
Sold their entire stake.
- Terns Pharmaceuticals-100%
- VeradermicsMANE-100%
- Cogent BiosciencesCOGT-100%
- Soleno Therapeutics-100%
- Viridian TherapeuticsVRDN-100%
- COMPASS PathwaysCMPS-100%
Holdings
- Abivax SAABVX
- Share
- 5.0%
- Value
- $55m
- Shares
- 414,899
+73%
- Bright Minds BiosciencesDRUG
- Share
- 3.6%
- Value
- $39m
- Shares
- 557,172
Held
- DBV Technologies S ADBVT
- Share
- 2.8%
- Value
- $30m
- Shares
- 1,844,758
-31%
- Odyssey TherapeuticsODTX
- Share
- 1.0%
- Value
- $11m
- Shares
- 575,000
New
- Eupraxia PharmaceuticalsEPRX
- Share
- 0.8%
- Value
- $9m
- Shares
- 1,350,000
Held
- Satellos BioscienceMSLE
- Share
- 0.6%
- Value
- $6m
- Shares
- 813,666
Held
- Valneva SEVALN
- Share
- 0.4%
- Value
- $4m
- Shares
- 763,199
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Trevi TherapeuticsTRVI | 8.7% | $95m | 5,094,668 | Held |
| Praxis Precision MedicinesPRAX | 8.3% | $91m | 271,116 | -20% |
| ErascaERAS | 6.9% | $76m | 4,127,412 | -66% |
| ArriVent BioPharmaAVBP | 5.3% | $58m | 1,682,097 | +90% |
| Abivax SAABVX | 5.0% | $55m | 414,899 | +73% |
| Tango TherapeuticsTNGX | 3.9% | $43m | 1,379,769 | -36% |
| Corvus PharmaceuticalsCRVS | 3.8% | $42m | 2,805,816 | Held |
| Bright Minds BiosciencesDRUG | 3.6% | $39m | 557,172 | Held |
| Sinovac BiotechSVA | 3.5% | $38m | 5,903,000 | Held |
| Tenax TherapeuticsTENX | 3.3% | $36m | 2,500,000 | +1100% |
| Aclaris TherapeuticsACRS | 3.2% | $35m | 6,694,637 | Held |
| Dyne TherapeuticsDYN | 3.2% | $35m | 1,557,466 | Held |
| Dianthus TherapeuticsDNTH | 3.2% | $35m | 353,998 | Held |
| Alto NeuroscienceANRO | 2.9% | $32m | 1,208,858 | +17% |
| DBV Technologies S ADBVT | 2.8% | $30m | 1,844,758 | -31% |
| SAB BiotherapeuticsSABS | 2.6% | $28m | 7,299,909 | -36% |
| MoonLake ImmunotherapeuticsMLTX | 2.5% | $27m | 1,400,000 | +40% |
| LB PharmaceuticalsLBRX | 2.4% | $26m | 800,000 | Held |
| Minerva NeurosciencesNERV | 2.2% | $24m | 4,322,747 | Held |
| Design TherapeuticsDSGN | 2.1% | $23m | 1,612,903 | Held |
| Oric PharmaceuticalsORIC | 1.8% | $20m | 1,848,786 | Held |
| Camp4 TherapeuticsCAMP | 1.7% | $19m | 4,246,568 | Held |
| Faeth TherapeuticsFTH | 1.6% | $18m | 722,020 | Held |
| Achieve Life SciencesACHV | 1.6% | $18m | 2,751,032 | New |
| Compass TherapeuticsCMPX | 1.6% | $17m | 7,757,060 | -19% |
| AN2 TherapeuticsANTX | 1.4% | $15m | 3,153,640 | Held |
| Editas MedicineEDIT | 1.1% | $12m | 3,555,250 | New |
| GeronGERN | 1.0% | $11m | 8,671,797 | Held |
| Odyssey TherapeuticsODTX | 1.0% | $11m | 575,000 | New |
| Eupraxia PharmaceuticalsEPRX | 0.8% | $9m | 1,350,000 | Held |
| OnKure TherapeuticsOKUR | 0.8% | $9m | 1,927,710 | Held |
| Olema PharmaceuticalsOLMA | 0.8% | $8m | 671,843 | Held |
| Monopar TherapeuticsMNPR | 0.8% | $8m | 90,500 | Held |
| Aura BiosciencesAURA | 0.8% | $8m | 1,166,667 | New |
| SurrozenSRZN | 0.6% | $7m | 260,000 | Held |
| ALX Oncology HoldingsALXO | 0.6% | $7m | 3,184,713 | Held |
| Satellos BioscienceMSLE | 0.6% | $6m | 813,666 | Held |
| Avalo TherapeuticsAVTX | 0.5% | $5m | 275,000 | New |
| PepGenPEPG | 0.4% | $4m | 2,325,000 | Held |
| Valneva SEVALN | 0.4% | $4m | 763,199 | New |
| Sera PrognosticsSERA | 0.3% | $3m | 1,650,440 | Held |
| Unicycive TherapeuticsUNCY | 0.2% | $3m | 550,000 | -69% |
| Instil BioTIL | 0.2% | $2m | 292,743 | Held |
| InMed PharmaceuticalsINM | 0.1% | $1m | 798,377 | New |
| Bolt BiotherapeuticsBOLT | <0.1% | $278,794 | 72,414 | Held |
| Pasithea TherapeuticsKTTA | <0.1% | $239,904 | 465,471 | -78% |
| Precision BiosciencesDTIL | <0.1% | $36,746 | 4,675 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 12.1% since 30 June 2025.
Where the money is
Health care91.8%
Other8.2%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.